BN Business News
Add your company to Business Communicator →

Business · 01/04/2010

National Institutes of Health to Grant Exclusive Patent License for Cancer Vaccine Development to Bavarian Nordic Immunotherapeutics

The National Institutes of Health is considering granting an exclusive patent license to Bavarian Nordic Immunotherapeutics to develop cancer vaccines based on PANVAC and tumor-associated antigens, as outlined in several U.S. patents and patent applications.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights